Designation granted by FDA recognizes the potential of plixorafenib, a novel, investigational paradox breaker and BRAF inhibitor, to provide substantial improvement over available therapies First ...

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene ...

February 11, 2008 — Investigators have found that insulin-like growth factor binding protein 7 (IGFBP7), a secreted protein, dramatically influences the ability of an activating BRAF mutation to ...

In 1972, Janet Rowley sat at her dining room table and cut tiny chromosomes from photographs she had taken in her laboratory. One by one, she snipped out the small figures her children teasingly ...

BRAF is the most commonly mutated gene associated with melanoma, found in more than 50 percent of patients. The gene encodes a cytoplasmic kinase that is a member of the MAPK signal-transduction ...

This article is based on a poster originally authored by Qiuyuan Yang, Kaiqiang Hu, Lei Liu, Tingting Guo, Haiyan Gu, Pengwei Pan, and Fang He. The study aimed to unravel the underlying processes that ...

Biomedical engineers have demonstrated that one of the most dangerous mutations found in skin cancers might moonlight as a pathway to mending a broken heart. The genetic mutation in the protein BRAF, ...